Gene therapy for NF2 tumors
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This trial tests a new gene therapy that is injected directly into tumors caused by NF2. It aims to help people whose tumors have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 16 years old.
- You must have a tumor that is linked to a mutation in the NF2 gene or lack of the Merlin protein.
- You must have at least one tumor that can be seen or felt and can be injected directly.
- Your blood counts, liver, kidney, and clotting function must be within safe limits.
- You cannot have had gene therapy for NF2 before.
- You cannot have severe seizures or other serious conditions, like unstable heart disease or poorly controlled high blood pressure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral drug called FCN-159 for people with NF2-related nerve sheath tumors that cannot be fully removed by surgery or have come back after surgery. It aims to see if the drug can shrink or slow the growth of these tumors.
This trial tests a combination of two investigational drugs for people with NF2-related tumors. The drugs target specific pathways to help shrink or slow growth of vestibular schwannomas and meningiomas.
This study is looking at new medicines for people with NF2-related schwannomatosis (NF2-SWN), a condition that causes tumors on nerves. It first tracks the natural course of the disease and may later test experimental drugs to help shrink or control tumors.
This trial tests a new drug called NV-001 for people with advanced solid tumors that are no longer responding to standard treatments. It aims to see if the drug is safe and can help shrink or slow tumor growth.
This trial tests a drug called selumetinib (a pill) for people with NF2-related schwannomatosis, a condition that causes non-cancerous tumors to grow on nerves, especially near the ears. The goal is to see if the drug can shrink or stabilize these tumors and protect hearing.
This trial tests a new medicine called PRG-N-01 for people with neurofibromatosis type 2 (NF2), a condition that causes tumors on nerves. The study aims to find the best dose and see if the medicine can shrink tumors or improve symptoms like hearing loss or pain, especially for those who cannot have surgery.
Hear when a new NF2 Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.